Search Results for: HRAS

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel TLR6 toll like receptor 6
  • ER-Phagosome pathway
  • MyD88:MAL(TIRAP) cascade initiated on plasma membrane
  • Toll Like Receptor TLR6:TLR2 Cascade
  • MyD88 deficiency (TLR2/4)
  • IRAK4 deficiency (TLR2/4)
  • Regulation of TLR by endogenous ligand
  • RSV-host interactions
  • Pam2csk4
Novel TLR9 toll like receptor 9
  • PI3K Cascade
  • Trafficking and processing of endosomal TLR
  • Toll Like Receptor 9 (TLR9) Cascade
  • Potential therapeutics for SARS
  • TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • MyD88 dependent cascade initiated on endosome
  • Chloroquine
  • Hydroxychloroquine
  • ISS-1018
  • Golotimod
  • CPG 10101
  • Tilsotolimod
Novel TP73 tumor protein p73
  • Activation of PUMA and translocation to mitochondria
  • TP53 Regulates Transcription of Genes Involved in Cytochrome C Release
  • TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain
  • TP53 Regulates Transcription of Caspase Activators and Caspases
  • TP53 Regulates Transcription of Death Receptors and Ligands
  • Regulation of TP53 Activity through Association with Co-factors
  • RUNX1 regulates transcription of genes involved in differentiation of HSCs
  • Zinc
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
  • Hepatocellular carcinoma
Novel TTC1 tetratricopeptide repeat domain 1
Novel TTC21A tetratricopeptide repeat domain 21A
Novel TTC28 tetratricopeptide repeat domain 28
Novel UBE3B ubiquitin protein ligase E3B
  • Antigen processing: Ubiquitination & Proteasome degradation
Novel UBE4B ubiquitination factor E4B
Novel USP29 ubiquitin specific peptidase 29
Novel USP42 ubiquitin specific peptidase 42
  • Ub-specific processing proteases
Novel VAV1 vav guanine nucleotide exchange factor 1
  • GPVI-mediated activation cascade
  • GPVI-mediated activation cascade
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • NRAGE signals death through JNK
  • Regulation of actin dynamics for phagocytic cup formation
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • FCERI mediated MAPK activation
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • CD28 dependent Vav1 pathway
  • G alpha (12/13) signalling events
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • VEGFR2 mediated vascular permeability
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • RHOA GTPase cycle
  • RAC1 GTPase cycle
  • RAC2 GTPase cycle
  • RHOG GTPase cycle
  • Erythropoietin activates RAS
  • Erythropoietin activates RAS
  • Regulation of signaling by CBL
  • FCGR3A-mediated phagocytosis
  • FCGR3A-mediated phagocytosis
  • Potential therapeutics for SARS
  • Azathioprine ADME
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
Novel ZBTB10 zinc finger and BTB domain containing 10
Novel ZBTB12 zinc finger and BTB domain containing 12
Novel ZDHHC9 zDHHC palmitoyltransferase 9
  • RAS processing
  • Maturation of spike protein
  • Syndromic X-linked mental retardation, including: Turner type (MRXST); Siderius type (MRXSSD) ; Cabezas type (MRXC); Raymond type (MRXSR); Type10 (MRXS10); Type14 (MRXS14); Mental retardation with isolated growth hormone deficiency (MRGH)
Novel ZFP36L2 ZFP36 ring finger protein like 2
  • M-decay: degradation of maternal mRNAs by maternally stored factors
ABR ABR activator of RhoGEF and GTPase
  • NRAGE signals death through JNK
  • G alpha (12/13) signalling events
  • RHOA GTPase cycle
  • RHOB GTPase cycle
  • RHOC GTPase cycle
  • CDC42 GTPase cycle
  • RAC1 GTPase cycle
  • RAC2 GTPase cycle
  • RAC3 GTPase cycle
ACTG1 actin gamma 1
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Gap junction degradation
  • Formation of annular gap junctions
  • Regulation of actin dynamics for phagocytic cup formation
  • Regulation of actin dynamics for phagocytic cup formation
  • EPHB-mediated forward signaling
  • EPH-ephrin mediated repulsion of cells
  • Adherens junctions interactions
  • Adherens junctions interactions
  • Recycling pathway of L1
  • Recycling pathway of L1
  • VEGFA-VEGFR2 Pathway
  • Interaction between L1 and Ankyrins
  • Interaction between L1 and Ankyrins
  • Cell-extracellular matrix interactions
  • RHO GTPases activate IQGAPs
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate Formins
  • RHO GTPases Activate Formins
  • MAP2K and MAPK activation
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF1 fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Clathrin-mediated endocytosis
  • RHOBTB2 GTPase cycle
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Sensory processing of sound by inner hair cells of the cochlea
  • Sensory processing of sound by outer hair cells of the cochlea
  • FCGR3A-mediated phagocytosis
  • FCGR3A-mediated phagocytosis
  • Regulation of CDH1 Function
  • Formation of the dystrophin-glycoprotein complex (DGC)
  • Formation of the dystrophin-glycoprotein complex (DGC)
  • Copper
  • Artenimol
AFDN afadin, adherens junction formation factor
  • (5R)-2-sulfanyl-5-[4-(trifluoromethyl)benzyl]-1,3-thiazol-4(5H)-one
AGTR1 angiotensin II receptor type 1
  • Peptide ligand-binding receptors
  • G alpha (q) signalling events
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • Valsartan
  • Olmesartan
  • Losartan
  • Candesartan cilexetil
  • Eprosartan
  • Telmisartan
  • Irbesartan
  • Forasartan
  • Saprisartan
  • Tasosartan
  • CYT006-AngQb
  • Azilsartan medoxomil
  • Fimasartan
  • Angiotensin II
  • Candesartan
  • Renal tubular dysgenesis
ANAPC1 anaphase promoting complex subunit 1
  • Inactivation of APC/C via direct inhibition of the APC/C complex
  • APC/C:Cdc20 mediated degradation of Cyclin B
  • Autodegradation of Cdh1 by Cdh1:APC/C
  • APC/C:Cdc20 mediated degradation of Securin
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Cdc20:Phospho-APC/C mediated degradation of Cyclin A
  • Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase
  • Regulation of APC/C activators between G1/S and early anaphase
  • APC/C:Cdc20 mediated degradation of mitotic proteins
  • Phosphorylation of the APC/C
  • APC-Cdc20 mediated degradation of Nek2A
  • Separation of Sister Chromatids
  • Senescence-Associated Secretory Phenotype (SASP)
  • Assembly of the pre-replicative complex
  • CDK-mediated phosphorylation and removal of Cdc6
  • Transcriptional Regulation by VENTX
  • Aberrant regulation of mitotic exit in cancer due to RB1 defects
  • Antigen processing: Ubiquitination & Proteasome degradation

Page 8 out of 16 pages